Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
Key points With the approval of new first-and second-line drugs and the establishment of treatment based on immune checkpoint inhibitors as standard treatment, treatment options for advanced hepatocellular carcinoma are more diverse than ever before. Therefore, clinical decision-making requires a mu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12962-023-00435-x |
| _version_ | 1827974543079112704 |
|---|---|
| author | Hongyu Gong Siew Chin Ong Fan Li Zhiying Weng Keying Zhao Zhengyou Jiang |
| author_facet | Hongyu Gong Siew Chin Ong Fan Li Zhiying Weng Keying Zhao Zhengyou Jiang |
| author_sort | Hongyu Gong |
| collection | DOAJ |
| description | Key points With the approval of new first-and second-line drugs and the establishment of treatment based on immune checkpoint inhibitors as standard treatment, treatment options for advanced hepatocellular carcinoma are more diverse than ever before. Therefore, clinical decision-making requires a multidisciplinary team to develop individualized treatment strategies according to the patients' disease and financial ability to pay. Here, we point out that lenvatinib, sintilimab plus bevacizumab and atezolizumab plus bevacizumab are more effective in the treatment of advanced hepatocellular carcinoma, but the cost of treatment is beyond the affordability of the patient. We outlined better drug purchase prices and health insurance reimbursement policies to enable patients to get the optimal treatment. |
| first_indexed | 2024-04-09T19:54:55Z |
| format | Article |
| id | doaj.art-1788ad40c44142da932b051be8cd5f09 |
| institution | Directory Open Access Journal |
| issn | 1478-7547 |
| language | English |
| last_indexed | 2024-04-09T19:54:55Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Cost Effectiveness and Resource Allocation |
| spelling | doaj.art-1788ad40c44142da932b051be8cd5f092023-04-03T05:28:30ZengBMCCost Effectiveness and Resource Allocation1478-75472023-03-0121111210.1186/s12962-023-00435-xCost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in ChinaHongyu Gong0Siew Chin Ong1Fan Li2Zhiying Weng3Keying Zhao4Zhengyou Jiang5School of Pharmaceutical Sciences, Universiti Sains MalaysiaSchool of Pharmaceutical Sciences, Universiti Sains MalaysiaIncubation Center for Scientific and Technological Achievements, Kunming Medical UniversitySchool of Pharmaceutical Science &Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical UniversitySchool of Public Health, Kunming Medical UniversitySchool of Management, Universiti Sains MalaysiaKey points With the approval of new first-and second-line drugs and the establishment of treatment based on immune checkpoint inhibitors as standard treatment, treatment options for advanced hepatocellular carcinoma are more diverse than ever before. Therefore, clinical decision-making requires a multidisciplinary team to develop individualized treatment strategies according to the patients' disease and financial ability to pay. Here, we point out that lenvatinib, sintilimab plus bevacizumab and atezolizumab plus bevacizumab are more effective in the treatment of advanced hepatocellular carcinoma, but the cost of treatment is beyond the affordability of the patient. We outlined better drug purchase prices and health insurance reimbursement policies to enable patients to get the optimal treatment.https://doi.org/10.1186/s12962-023-00435-xCost-effectiveness analysisSorafenibLenvatinibAtezolizumab plus bevacizumabSintilimab plus bevacizumabAdvanced hepatocellular carcinoma |
| spellingShingle | Hongyu Gong Siew Chin Ong Fan Li Zhiying Weng Keying Zhao Zhengyou Jiang Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China Cost Effectiveness and Resource Allocation Cost-effectiveness analysis Sorafenib Lenvatinib Atezolizumab plus bevacizumab Sintilimab plus bevacizumab Advanced hepatocellular carcinoma |
| title | Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China |
| title_full | Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China |
| title_fullStr | Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China |
| title_full_unstemmed | Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China |
| title_short | Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China |
| title_sort | cost effectiveness analysis of sorafenib lenvatinib atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in china |
| topic | Cost-effectiveness analysis Sorafenib Lenvatinib Atezolizumab plus bevacizumab Sintilimab plus bevacizumab Advanced hepatocellular carcinoma |
| url | https://doi.org/10.1186/s12962-023-00435-x |
| work_keys_str_mv | AT hongyugong costeffectivenessanalysisofsorafeniblenvatinibatezolizumabplusbevacizumabandsintilimabplusbevacizumabforthetreatmentofadvancedhepatocellularcarcinomainchina AT siewchinong costeffectivenessanalysisofsorafeniblenvatinibatezolizumabplusbevacizumabandsintilimabplusbevacizumabforthetreatmentofadvancedhepatocellularcarcinomainchina AT fanli costeffectivenessanalysisofsorafeniblenvatinibatezolizumabplusbevacizumabandsintilimabplusbevacizumabforthetreatmentofadvancedhepatocellularcarcinomainchina AT zhiyingweng costeffectivenessanalysisofsorafeniblenvatinibatezolizumabplusbevacizumabandsintilimabplusbevacizumabforthetreatmentofadvancedhepatocellularcarcinomainchina AT keyingzhao costeffectivenessanalysisofsorafeniblenvatinibatezolizumabplusbevacizumabandsintilimabplusbevacizumabforthetreatmentofadvancedhepatocellularcarcinomainchina AT zhengyoujiang costeffectivenessanalysisofsorafeniblenvatinibatezolizumabplusbevacizumabandsintilimabplusbevacizumabforthetreatmentofadvancedhepatocellularcarcinomainchina |